Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) is a late-stage biopharmaceutical company focused on the development of the therapeutic immunomodulating drug candidate voclosporin for the treatment of lupus nephritis. The company leverages its team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database to inform and guide its clinical development plans within this therapeutic area. For more information, visit the company’s website at www.auriniapharma.com